0.0085  -0.107 (-92.64%)		04-11 15:58
Open: 0.015 High: 0.02 Volume: 1,943,400		Pre. Close: 0.1155 Low: 0.0075 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Otonomy, Inc., a biopharmaceutical firm established in 2008 and headquartered in San Diego, California, concentrates on pioneering treatments for neurotological disorders throughout the United States. Its robust pipeline includes several programs: OTO-313, a sustained-release formulation of the N-methyl-D-aspartate receptor antagonist gacyclidine, currently in Phase II clinical trials for addressing tinnitus; and OTO-413, a sustained-exposure brain-derived neurotrophic factor, which is undergoing Phase IIa studies to mend cochlear synaptopathy and alleviate speech-in-noise hearing difficulties. The company is also advancing OTO-510, an otoprotectant designed to prevent hearing loss induced by cisplatin, along with OTO-825, a gene therapy aimed at congenital hearing loss. Additionally, OTO-6XX is being developed to stimulate hair cell repair and regeneration for severe hearing impairment. Otonomy holds licensing agreements with the University of California and DURECT Corporation, and has a strategic alliance with Applied Genetic Technologies Corporation focused on gene therapy solutions for congenital hearing loss.

Wed, 29 Mar 2023
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board - PR Newswire

Tue, 20 Dec 2022
Otonomy shuts up shop, lays off all employees after string of ear drug failures - Fierce Biotech

Tue, 20 Dec 2022
Otonomy plans to dissolve - www.drugdiscoverytrends.com

Mon, 01 Aug 2022
Otonomy gives up on experimental tinnitus drug after disappointing Phase 2 trial - www.drugdiscoverytrends.com

Wed, 17 Nov 2021
Otonomy to Present at Society for Neuroscience Annual Meeting, November 3-7 - The Hearing Review

Mon, 03 Aug 2020
Otonomy Announces Exclusive License Agreement with Kyorin - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date